title: Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
abstract: The microtubule-associated protein tau accumulates as cytoplasmic inclusions in Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). We investigated the immunoreactivity of tau-positive structures using a panel of antibodies to epitopes spanning the entire length of the tau molecule. In ethanol-fixed brain tissues, most antibodies to the microtubule-binding domain (MBD) required formic acid (FA) treatment to stain tau inclusions in PSP and CBD. This is in contrast with the intense labeling of neurofibrillary tangles in AD without FA treatment. Pick bodies (PiB) in PiD showed an intermediate pattern with respect to the immunoreactivity of the MBD because accumulated tau in PiB mostly lacks the insertion of exon 10, and the proportion of tau phosphorylated at Ser262 is smaller than in other abnormal tau structures. Such immunohistochemical profiles appeared to correlate with the occurrence of the smeared tau on immunoblot analysis of brain homogenate. The smeared tau was more abundant in AD and PiD than in PSP and CBD. Since the smeared tau was N-terminally truncated and was characteristic of advanced forms of modified tau, these findings suggest that tau accumulated in AD and PiD was processed more markedly than that in PSP and CBD. The MBD of tau may be masked in the presence of the intact N terminus and require FA treatment for antibody recognition in tissue sections. Advanced modification may expose the MBD in brain tissues of AD and PiD. It is suggested that the processing of abnormally accumulated tau characterizes the pathophysiology of each tauopathy.
authors.affiliation: Department of Psychogeriatrics, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, 156-8585 Tokyo, Japan. arai@prit.go.jp
authors.forename: Tetsuaki
authors.initials: T
authors.lastname: Arai
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikeda
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Akiyama
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Shuji
authors.initials: S
authors.lastname: Iritani
authors.forename: Koichi
authors.initials: K
authors.lastname: Ishiguro
authors.forename: Saburo
authors.initials: S
authors.lastname: Yagishita
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Oda
authors.forename: Toshinari
authors.initials: T
authors.lastname: Odawara
authors.forename: Eizo
authors.initials: E
authors.lastname: Iseki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D000906:Antibodies / Q000378:metabolism; D000937:Antigen-Antibody Reactions; D001665:Binding Sites; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D008297:Male; D008870:Microtubules / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism; D020774:Pick Disease of the Brain / Q000378:metabolism* / Q000473:pathology; D020955:Striatonigral Degeneration / Q000378:metabolism*; D013494:Supranuclear Palsy, Progressive / Q000378:metabolism* / Q000473:pathology; D016875:tau Proteins / Q000145:classification / Q000276:immunology / Q000378:metabolism*
chemical_list: D000906:Antibodies; D010446:Peptide Fragments; D016875:tau Proteins